Peer-Reviewed Evidence
The Science Behind
Stem Cell Therapy
A plain-language review of peer-reviewed research on mesenchymal stem cells, and why how they are made matters as much as what they are.
Introduction
Why This Page Exists
If you are considering stem cell therapy, you probably have one very reasonable question: “Is there real science behind this?”
The answer is yes, and there is a lot of it. Thousands of peer-reviewed studies have been published on mesenchymal stem cells (MSCs), the type of stem cells used at the Cellular Performance Institute (CPI). This page walks you through what that science actually shows, explained in plain language.
We also want to be upfront about something important: most of the research published on stem cells over the past two decades was done using older manufacturing methods. At CPI, we use a more advanced approach, Hypoxic Mesenchymal Stem Cells grown without any animal products. We will explain what that means and why it matters as we go through the research.
Fundamentals
What Are Mesenchymal Stem Cells?
Think of mesenchymal stem cells (MSCs) as your body’s repair crew. They are found naturally in bone marrow, fat tissue, umbilical cord tissue, and other places throughout the body. When tissues are damaged, MSCs migrate to the injury site, help calm down inflammation, and support the rebuilding of healthy tissue.
What makes them especially useful as a therapy is that they can:
- Reduce inflammation — they act like a natural “off switch” for runaway inflammatory signals
- Communicate with the immune system — helping it respond more appropriately rather than attacking healthy tissue
- Differentiate into multiple cell types — meaning they can help regenerate cartilage, bone, fat tissue, and more depending on what the body needs (this is debated once injected but there’s plenty of literature that supports this, especially for hypoxic stem cells)
- Survive and function in damaged environments — particularly environments with low oxygen, which is where most injuries and degenerative conditions occur
Section 1 — Manufacturing Science
Why CPI Uses Hypoxic MSCs, and What the Science Shows
The Gold Standard: Growing Stem Cells the Way the Body Does
Here is something most people do not know: when stem cells live inside your body — inside bone marrow, inside cartilage, inside the discs of your spine — they exist in a low-oxygen environment. The oxygen level inside your bone marrow is roughly 2–7%. Inside cartilage and spinal discs, it can be as low as 1–5%.
Most stem cell labs around the world grow their cells at room air oxygen levels, about 20% oxygen. That is four to ten times higher than what stem cells experience inside your body. It is a bit like taking a deep-sea fish and putting it in a freshwater lake. The fish is the same species, but its environment has changed in a way that affects how it behaves.
CPI grows its stem cells in low-oxygen (hypoxic) conditions, specifically at 5% oxygen, to match the natural environment where these cells come from and where they will be working inside your body.
What a Peer-Reviewed Study Found
Study Reference
Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome
Elabd et al., Journal of Translational Medicine, 2018 | PMC6086019
A 2018 study published in the Journal of Translational Medicine compared human bone marrow MSCs grown in standard (20% oxygen) conditions versus hypoxic (5% oxygen) conditions. This was a rigorous scientific study using whole-genome mRNA sequencing, essentially reading every gene the cells were expressing.
Key Findings
- 50% more clonogenicity — the ability of a single cell to grow into a full colony of cells (37.1% vs. 24.4%). More seeds sprouting means more therapeutic cells available to do the work.
- Greater differentiation potential into cartilage and fat tissue — hypoxic cells showed significantly higher expression of cartilage-building genes (COL2A1 and aggrecan), better equipped to help rebuild cartilage, especially relevant for osteoarthritis, joint degeneration, and disc disease.
- Better survival and anti-inflammatory activity — hypoxic cells expressed higher levels of protective enzymes (GPX3 and TXNIP) that shield cells from oxidative stress. CXCL5 was 25 times lower in hypoxic cells, meaning they are more “immune privileged.”
- Enhanced migration and angiogenesis — hypoxic cells expressed more genes related to moving to injury sites and supporting new blood vessel formation, which is critical for healing.
Note: This study was conducted specifically on hypoxic bone marrow MSCs. CPI uses umbilical cord derived MSCs. The data in this section does not reflect CPI’s actual manufacturing approach. The research sections that follow draw on the broader body of stem cell science, which was largely conducted using standard (non-hypoxic) manufacturing methods. As the data above shows, CPI’s hypoxic process produces cells with meaningfully superior properties compared to those older methods.
Section 2 — Safety & Quality
Why “Animal-Free” Manufacturing Is a Safety Issue, Not Just a Marketing Term
The Problem with Fetal Calf Serum
For decades, the standard way to grow stem cells in a lab was to feed them with fetal calf serum (FCS), a product derived from the blood of unborn calves. It works well enough to grow cells, but it introduces a serious problem: the cells absorb animal proteins during the growth process, and those foreign proteins travel along with the cells when they are injected into a patient.
Think of it this way: imagine you ordered a meal at a restaurant, but the kitchen used a cutting board that had been used to prepare something you are allergic to. The dish itself might be fine, but cross-contamination is a real risk.
Study Reference
Animal-Free vs. FCS Manufacturing: Safety and Quality Comparison
Riordan et al., Journal of Translational Medicine, 2015 | PMC4504159
Safety Findings
- Patients given cells grown in FCS-based media have been documented to develop antibodies against the animal proteins absorbed by the cells — the same kind of immune reaction your body mounts against a foreign invader.
- In some documented cases, this immune response led to Arthus reactions (a type of severe local immune reaction) and anaphylaxis (a life-threatening allergic reaction) in patients receiving stem cell infusions.
- These reactions occurred not because the stem cells themselves were rejected, but because the patient’s immune system recognized and attacked the lingering animal proteins absorbed during manufacturing.
Quality Findings
- Cells grown in human platelet lysate media (the animal-free approach) showed equivalent or superior proliferation rates compared to FCS — you get just as many cells, or more, without the safety risk.
- The cells retained all of their defining characteristics — the same surface markers (CD105, CD73, CD90), the same ability to differentiate into bone, cartilage, and fat tissue.
- Results were consistent across multiple cell lots and independent laboratories, confirming this is a reliable, reproducible manufacturing approach.
How this applies to CPI: CPI grows its Hypoxic Mesenchymal Stem Cells using no animal reagents or byproducts throughout the entire manufacturing process. The cells you receive have never been exposed to fetal calf serum or any other animal-derived component. This is a meaningful distinction from most other stem cell providers.
Putting It Together: What “Advanced Manufacturing” Actually Means for You
When people ask whether stem cell therapy is backed by science, the answer is yes — there is a robust and growing body of peer-reviewed research. But the follow-up question that matters just as much is: “Are the cells being used the best version of those cells that science currently knows how to make?”
At CPI, the answer is also yes.
Feature
Standard MSCs (older technology)
CPI’s Hypoxic, Animal-Free MSCs
Oxygen during manufacturing
20% (room air)
5% (matches body’s natural environment)
Clonogenicity (cell fitness)
Baseline
50% higher
Cartilage-building potential
Baseline
Significantly enhanced
Anti-inflammatory activity
Baseline
25x lower pro-inflammatory signaling
Animal product exposure
Yes (fetal calf serum)
None
Immune reaction risk
Documented cases
Eliminated
The broader body of stem cell research, which you will find in the condition-specific sections below, was conducted using older manufacturing methods. That research still shows meaningful therapeutic effects. CPI’s approach takes that same foundation and builds on it with the most advanced manufacturing science currently available.
Condition Area
Degenerative Disc Disease and Chronic Lower Back Pain
Why Your Disc Is One of the Hardest Places in the Body to Heal
Your intervertebral discs are the shock-absorbing cushions between the bones of your spine. They are made of a tough outer ring (the annulus fibrosus) and a soft, gel-like center (the nucleus pulposus). When healthy, your disc is like a water balloon — firm on the outside, fluid and springy on the inside, able to absorb the forces of daily movement.
Here is the critical detail: your discs have almost no blood supply. They are the largest avascular (blood-vessel-free) structures in the human body. Nutrients have to diffuse slowly through the disc from the edges, the way water soaks through a very thick sponge.
- Oxygen levels inside a healthy disc are already very low — between 1% and 5%
- In a degenerated disc, that oxygen level drops even further
- When tissues are damaged, the body normally floods the area with blood-borne repair cells, but the disc cannot do this
- This is why disc degeneration is considered largely irreversible — the disc simply cannot mount the repair response that other tissues can
This is exactly why CPI’s use of Hypoxic Mesenchymal Stem Cells is so significant for disc treatment specifically. The cells are grown in 5% oxygen, matching the disc’s natural environment, so when they are injected directly into the disc, they are already adapted to survive and function in that low-oxygen, nutrient-poor space.
Note on the research below: Several of the studies in this section used standard (non-hypoxic) culture conditions or older manufacturing methods. As you will see, those studies still showed meaningful results. CPI uses hypoxic manufacturing, which the science shows produces cells better suited to the disc environment. Think of it this way: if older methods produced these results, the more advanced approach has every reason to perform at least as well, and the biological data suggests it should perform better.
What the Research Shows
Study 1 of 5
Why Hypoxic Cells Are Specifically Built for the Disc
Elabd et al., Journal of Translational Medicine, 2018 | PMC6086019
This is the foundational study for understanding why CPI’s manufacturing approach matters for disc treatment specifically. Researchers compared bone marrow MSCs grown at room air (20% oxygen) versus hypoxic conditions (5% oxygen) and found that hypoxic cells expressed significantly higher levels of KRT19 — a gene that is considered a specific marker of nucleus pulposus cells (the cells that make up the interior of a healthy disc). They also showed dramatically higher expression of aggrecan (ACAN) and collagen type II (COL2A1), which are the exact proteins that make up the disc’s structural matrix.
In plain language: when you grow stem cells in low oxygen, they start to “speak the language” of disc cells. They express the same genes, produce the same proteins, and are biologically primed to integrate into and support disc tissue. Cells grown in room air do not show this same profile.
The study also noted that the oxygen partial pressure inside the bone marrow (where these cells naturally live) is 2–7%, and inside cartilage and the disc is 1–5%. Growing cells at 5% oxygen is not an arbitrary choice — it is matching the cells’ native environment and the environment where they will be working.
Study 2 of 5
The First Human Clinical Data — Direct Disc Injection with Hypoxic Cells
Elabd et al., Journal of Translational Medicine, 2016 | PMC307610278
This is the first published human clinical study of direct intra-discal injection of hypoxic cultured bone marrow MSCs. Five patients with degenerative disc disease — all of whom had already failed standard treatments including physical therapy, oral medications, and epidural steroid injections — received direct injections of their own (autologous) hypoxic cultured MSCs into the affected disc. The cells were grown at 5% oxygen, in human platelet lysate media with no animal products. The patients were then followed for 4 to 6 years, one of the longer follow-up periods in the stem cell disc literature.
What the Data Showed
- Zero serious adverse events across all 5 patients over the entire 4–6 year follow-up period. No tumors, no infections, no disc damage attributable to the procedure.
- All 5 patients reported overall improvement in quality of life post-treatment
- All 5 patients reported improvement in strength
- 4 out of 5 patients reported improvement in mobility
- MRI scans showed no abnormalities or neoplasms in the treated area
- In 2 of the 5 patients, MRI measurements showed actual reduction in disc protrusion size
- The data showed a positive correlation between the number of cells injected and the degree of improvement reported
Note on this research and CPI: This study used the same hypoxic, animal-free manufacturing approach that CPI uses. The cells injected were grown at 5% oxygen in human platelet lysate, directly matching CPI’s protocol. This is using older technology data with bone marrow derived stem cells, a caveat. Only CPI uses umbilical cord derived MSC stem cells.
Study 3 of 5
The Largest Case Series — 33 Patients, 6-Year Follow-Up, MRI-Confirmed Results
Centeno et al., Journal of Translational Medicine, 2017 | PMC5610473
Thirty-three patients with degenerative disc disease and associated radicular pain, all of whom had failed conservative care for an average of over 6 years, received direct intradiscal injections of culture-expanded autologous bone marrow MSCs grown in hypoxic conditions.
What the Data Showed
- No serious adverse events — no deaths, no infections, no tumors in any patient
- Pain scores improved significantly at 3 months, 4 years, and 5 years post-treatment
- 90% of patients reported improvement at the 3-year mark
- 60% average overall improvement reported at 3 years
- 85% of patients who had post-treatment MRI scans showed a measurable reduction in disc bulge size, with an average reduction of 23%
- Functional disability scores improved beyond the clinically meaningful threshold at all time points except 12 months
- Results held through 6 years of follow-up
Study 4 of 5
10 Years of Follow-Up Data — The Longest Published Record
Hooper et al., Biomedicines, 2025 | PMID 41153652
This 2025 study from Emory University School of Medicine and the Centeno-Schultz Clinic reports the longest known follow-up data for intradiscal MSC therapy — up to 10 years after treatment. Thirteen patients who received intradiscal culture-expanded MSC injections between 2015 and 2016 were tracked through 10 years of follow-up.
What the Data Showed
- Significant reductions in pain and disability at 6 months, 3 years, and 6 years (all statistically significant, p < 0.01)
- At 6 years: average pain score decreased by 2.5 points on a 10-point scale, disability index improved by 24 points, and overall patient-reported improvement was 60%
- At 10 years: average patient-reported improvement was 78.1% among the 7 patients who responded at that time point
- Zero adverse events reported across the entire follow-up period
Study 5 of 5
The Most Rigorous Trial — A Double-Blind, Randomized Controlled Study
Vadalà et al., JOR Spine, 2025 | PMID 40462867 (DREAM Study)
This is the most scientifically rigorous study in this section — a Phase IIB double-blind randomized controlled trial conducted at a major Italian university hospital. Fifty-two patients with moderate-to-advanced multilevel disc degeneration unresponsive to conservative treatment were randomized to receive either MSC injections or a sham (placebo) procedure. Neither the patients nor the treating physicians knew who received what.
What the Data Showed
- MSC injections were well-tolerated with no major adverse events
- The MSC group showed significant structural improvements on MRI — disc height increased measurably at 3 and 6 months compared to the sham group
- T2 relaxation times (a measure of disc hydration and health) showed improvement trends in the MSC group
- Both groups showed clinical improvement in pain and disability scores, without a statistically significant difference between them at 6 months
How to understand this result: The structural improvements on MRI are meaningful — the discs actually changed in measurable ways in the MSC group. The fact that both groups improved clinically at 6 months likely reflects the short follow-up period (6 months may not be long enough for the full regenerative effect) as well as the well-documented “sham effect” in pain research. The safety profile was excellent, and the structural data provides objective evidence of biological activity. This study used standard (non-hypoxic) culture conditions.
Putting the Disc Research Together
What Was Measured
What the Research Found
Safety
Zero serious adverse events (tumors, infections, paralysis) across all studies
Pain relief
Significant, sustained improvements through 6–10 years
Function
Meaningful improvement in disability and quality of life
Disc structure on MRI
Reduction in bulge size (85% of patients in one study), increases in disc height, improved hydration
Durability
78% average improvement at 10 years in one study
Condition Area
Knees, Hips, and Orthopedic Joints
The Most Injured Joints in the Human Body
Knees and hips are among the most commonly injured and degenerated joints in the body, and for good reason. Your knees absorb two to three times your body weight with every step you take. Your hips carry the entire load of your upper body and transfer force every time you walk, climb stairs, or stand up from a chair. Over a lifetime, that adds up to an enormous amount of wear.
Knee pain is one of the most common reasons people visit a doctor in the United States, affecting an estimated 25% of adults. Hip pain, including osteoarthritis and avascular necrosis (bone death from loss of blood supply), affects millions more.
The same biology that makes stem cells effective for disc regeneration also applies to joints. Joints share key characteristics with discs: they contain cartilage that has poor blood supply and limited natural healing capacity, they exist in low-oxygen environments, and they degenerate through a combination of mechanical wear and chronic inflammation.
Note: This study was conducted specifically on hypoxic bone marrow MSCs. CPI uses umbilical cord derived MSCs. The data in this section does not reflect CPI’s actual manufacturing approach. The research sections that follow draw on the broader body of stem cell science, which was largely conducted using standard (non-hypoxic) manufacturing methods. As the data above shows, CPI’s hypoxic process produces cells with meaningfully superior properties compared to those older methods.
What the Research Shows on Knees
The Most Comprehensive Recent Analysis
Meta-Analysis of Randomized Controlled Trials, 2025
Luo et al., Stem Cell Research and Therapy, 2025 | PMID 40055739 | PMC11887158
This 2025 systematic review and meta-analysis specifically focused on patients who had not had surgery and received MSC injections without other add-on therapies — a clean test of what MSCs alone can do. Eight randomized controlled trials involving 502 patients were included.
Key Findings
- MSCs significantly improved WOMAC scores at both 6 months (p = 0.01) and 12 months (p = 0.03) — the gold-standard measurement tool for knee osteoarthritis, scoring pain, stiffness, and physical function.
- MSCs significantly improved pain scores (VAS) at both 6 months (p = 0.0008) and 12 months (p = 0.0003)
- MSCs significantly improved KOOS scores — a comprehensive knee outcomes measure covering symptoms, pain, daily activities, sports and recreation, and quality of life — at both 6 and 12 months
- No significant difference in adverse events between the MSC group and the control group
The Largest Dose-Optimization Analysis
6 RCTs, 300 Patients, 2025
Shariatzadeh et al., PMC, 2025 | PMC12398016
Key Findings
- The pooled treatment effect (standardized mean difference of −1.35) indicated a moderate to large clinical benefit from MSC injections at 12 months
- Seven of eight treatment comparisons showed statistically significant improvement in WOMAC scores
- MSC therapy appeared to outperform traditional treatments including hyaluronic acid injections and corticosteroids
- Lower doses (25 million cells or fewer) were associated with significant improvement, suggesting the mechanism is biological signaling, not a simple “more is better” equation
Note: These studies used a range of MSC sources and standard culture conditions. None used hypoxic manufacturing. The results represent a floor, not a ceiling, for what MSC therapy can achieve in joints. The dosing protocols are inline with CPI’s recommended dosing for best results.
An Honest Look at the Nuance
What Placebo-Controlled Trials Tell Us
Frontiers in Medicine, 2025 | CRD420251026818
A 2025 analysis of eight randomized controlled trials (467 patients) examined how much of the improvement seen in MSC knee trials was due to the cells themselves versus the “context” of receiving a treatment. The researchers found that contextual factors accounted for roughly 60% of the pain improvement at 6 months, with the MSCs themselves contributing the remaining 40%.
This does not mean MSC therapy “doesn’t work.” It means that, like most medical treatments, it works through multiple pathways. The researchers themselves noted that “patients truly feel better” and that this finding “does not negate the biological potential of MSCs.”
What this research actually highlights is a critical manufacturing insight: if standard MSC preparations produce meaningful improvement even when a significant portion of the benefit is contextual, then cells that are biologically more potent — grown in conditions that match the joint environment — have a stronger foundation to build real, measurable structural improvement. This is exactly the direction CPI is already in.
What the Research Shows on Hips
The Gold-Standard Analysis for Hip Joint Necrosis
17 Studies, 1,019 Hips, Network Meta-Analysis, 2024
Wang et al., Stem Cell Research and Therapy, 2024 | Full Article
This is one of the most comprehensive analyses ever conducted on regenerative therapies for osteonecrosis of the femoral head (ONFH) — the condition where the ball of the hip joint loses its blood supply and begins to die. Left untreated, ONFH typically progresses to femoral head collapse and requires total hip replacement surgery. More than 10,000 new cases are diagnosed annually in the United States alone.
The researchers used a Bayesian network meta-analysis — a sophisticated statistical method that allows simultaneous comparison of multiple treatments against each other. They analyzed 17 clinical trials involving 1,019 hips across six different treatment approaches.
Key Findings
- MSCs ranked first among all six regenerative therapies for both key outcomes measured
- For preventing disease progression: patients treated with MSCs were approximately 90% less likely to experience disease progression compared to core decompression alone
- For preventing conversion to total hip replacement surgery: patients treated with MSCs were approximately 94% less likely to need a total hip replacement
- BMAC (bone marrow concentrate) ranked second, but with significantly weaker odds ratios than expanded MSCs
- Autologous bone graft, free vascularized bone graft, and platelet-rich plasma showed no statistically significant advantage over core decompression alone
90%
Less likely to experience disease progression (hip necrosis)
94%
Less likely to need total hip replacement surgery
#1
MSCs ranked first among all six regenerative therapies tested
Putting the Joint Research Together
What Was Measured
What the Research Found
Knee pain (WOMAC, VAS)
Significant improvement at 6 and 12 months across multiple RCTs
Knee function (KOOS)
Significant improvement in symptoms, daily activities, sports, quality of life
Hip disease progression
90% reduction in progression rate with MSCs vs. core decompression
Hip replacement avoidance
94% reduction in total hip replacement rate with MSCs
MSCs vs. other regenerative treatments
MSCs ranked first among all six approaches tested for hip necrosis
Safety across all joint studies
No significant increase in adverse events vs. comparison groups
Condition Area
Stroke and Neurological Recovery
What Happens to the Brain During a Stroke
A stroke is a medical emergency that occurs when blood flow to part of the brain is suddenly cut off. Without a steady supply of blood, brain cells begin to die within minutes — at a rate of approximately 1.9 million neurons per minute during an active stroke. The damage that results can affect movement, speech, memory, and the ability to perform basic daily tasks.
A stroke is a medical emergency that occurs when blood flow to part of the brain is suddenly cut off. Without a steady supply of blood, brain cells begin to die within minutes — at a rate of approximately 1.9 million neurons per minute during an active stroke. The damage that results can affect movement, speech, memory, and the ability to perform basic daily tasks.
Stroke is the leading cause of long-term disability in the United States, and the fifth leading cause of death. Every year, approximately 795,000 Americans experience a stroke. Of those who survive, roughly two-thirds are left with some degree of permanent neurological impairment.
Note on the research in this section: The studies below used standard MSC preparations, not CPI’s hypoxic, animal-free protocol. The brain, like the disc and joint cartilage, is a low-oxygen environment, particularly in the damaged tissue surrounding a stroke. CPI’s hypoxic cells are biologically better adapted to function in low-oxygen, inflamed environments.
The Largest Clinical Meta-Analysis on Record
30 Trials, 1,217 Patients, 2024
Shen Z, et al., Stem Cells Translational Medicine, 2024 | PMID 39159204 | PMC11386217
What the Data Showed in Randomized Controlled Trials
- Neurological function improved significantly — patients treated with MSCs showed a meaningful reduction in NIHSS scores (National Institutes of Health Stroke Scale) of −1.69 points (p < 0.001)
- Daily functioning improved significantly — patients treated with MSCs showed improvement on the modified Rankin Scale (mRS), with a mean difference of −0.26 (p = 0.04)
- Mortality was reduced by 56% — stroke patients treated with MSCs had a mortality risk ratio of 0.44 compared to controls (p < 0.001)
- No increase in serious adverse events — the safety profile of MSC treatment was equivalent to standard care. The most commonly reported side effects were fever and headache, both temporary.
To put the mortality finding in perspective: most drugs that reduce stroke mortality by even 10–15% are considered major breakthroughs. A 56% reduction in mortality across 15 randomized controlled trials is a remarkable signal.
Functional Recovery Focus
Intravenous MSCs for Acute and Subacute Stroke, 2024
Frontiers in Stroke, 2024 | CRD42023457655
This meta-analysis focused specifically on intravenous MSC delivery in patients with acute and subacute ischemic stroke. Four randomized controlled trials involving 97 patients were analyzed.
What the Data Showed
- Modified Rankin Scale scores improved significantly — MSC treatment was superior to placebo with a mean difference of −0.95 (p < 0.0001). On a scale that runs from 0 (no symptoms) to 6 (death), a nearly 1-point improvement represents the difference between needing assistance with daily activities versus managing independently.
- Barthel Index scores improved significantly — MSC patients scored an average of 21.36 points higher than placebo patients (p < 0.001). On a 100-point scale, a 21-point improvement is the difference between needing full assistance and being largely self-sufficient.
- Safety was acceptable — no significant increase in adverse events, mortality, or stroke recurrence compared to placebo
The Ongoing Clinical Trial Landscape
What Is Currently Being Studied, 2024
Morales et al., PMC, 2024 | PMC11021793
Key Findings
- Treatment tolerance was very high across all completed trials — of 109 serious adverse events reported across one large trial involving 38 patients, only 2 were directly related to the MSC treatment itself, and both resolved completely
- Motor function improvements were documented in completed trials, particularly in patients with more severe initial strokes
- MSCs help stroke recovery through four documented pathways: (1) promoting survival of remaining brain cells, (2) reducing inflammatory damage in the days and weeks after stroke, (3) stimulating neurogenesis, and (4) supporting repair of damaged brain tissue
Putting the Stroke Research Together
What Was Measured
What the Research Found
Neurological deficit (NIHSS)
Significant improvement vs. standard care in RCTs (p < 0.001)
Disability level (modified Rankin Scale)
Significant improvement vs. placebo in multiple analyses
Daily living independence (Barthel Index)
21-point improvement vs. placebo (p < 0.001)
Mortality
56% reduction in death rate vs. standard care in RCTs
Safety
No significant increase in serious adverse events
Mechanism
Anti-inflammatory, neuroprotective, neurogenic, angiogenic
Condition Area
Heart Failure and Cardiac Disease
When the Heart Can No Longer Keep Up
Your heart is a muscle, and like any muscle, it can be damaged. Heart failure does not mean the heart has stopped. It means the heart muscle has been weakened to the point where it can no longer pump blood as efficiently as the body needs. The result is a cascade of consequences: fluid builds up in the lungs and legs, the body does not get enough oxygen, and everyday activities like walking to the mailbox or climbing a flight of stairs become exhausting.
Heart failure affects approximately 6.7 million adults in the United States and is the leading cause of hospitalization in people over 65. Despite significant advances in medications, the five-year survival rate for heart failure is worse than many cancers — roughly 50% of patients die within five years of diagnosis.
The core problem with heart failure is that the heart has almost no ability to regenerate damaged muscle cells. When a heart attack or chronic disease kills cardiomyocytes — the cells that do the actual pumping — those cells are replaced by scar tissue. Scar tissue does not contract. It does not pump. Think of the damaged heart like a car engine with a cracked cylinder. Medications are like adding better fuel and oil. MSCs are like sending in a repair crew to address the cracked cylinder itself.
Note on the research in this section: All four studies below used standard MSC preparations, none used CPI’s hypoxic, animal-free protocol. The heart muscle, in the damaged zones around a heart attack or in a chronically failing heart, is considered a low-oxygen environment. CPI’s hypoxic MSCs are grown at 5% oxygen, which, as one of the 2025 studies specifically noted, “activates survival pathways under low-oxygen conditions, strengthening their therapeutic potential in heart failure treatment.”
The Most Comprehensive RCT Meta-Analysis
17 Trials, 1,684 Patients, 2024
Baghal Asghari et al., Journal of Translational Medicine, 2024 | PMID 39174960
What the Data Showed
- Mortality was significantly reduced — patients who received MSCs had a 22% lower risk of death compared to controls (risk ratio 0.78, p = 0.04)
- Heart pumping function improved significantly — LVEF increased by an average of 3.38 percentage points (p < 0.001). A 3–5 point improvement in LVEF is considered clinically meaningful and is associated with reduced hospitalization and improved survival.
- The heart physically shrank back toward normal size — LVESV decreased by an average of 9.14 mL and LVEDV decreased by 8.34 mL (both p < 0.001). This “reverse remodeling” is one of the most meaningful structural changes possible in heart failure treatment.
- Scar tissue was measurably reduced — standardized mean difference of −0.32 (p = 0.02). This is a remarkable finding: scar tissue in the heart is generally considered permanent.
- Symptom class improved significantly — NYHA class improved by an average of 0.19 points (p = 0.006)
- Heart failure biomarkers improved — BNP decreased significantly (p = 0.01)
- Quality of life improved significantly — Minnesota Living with Heart Failure Questionnaire scores improved by an average of 11.55 points (p < 0.001)
- Exercise capacity improved — six-minute walk test distance improved by an average of 36.86 meters (p = 0.001)
- Rehospitalization was reduced — particularly in patients who received autologous MSCs, where rehospitalization was reduced by 33% (p = 0.008)
14 Randomized Controlled Trials
LVEF Improvement and Hospitalization Reduction, 2023
Hassanzadeh et al., PMC, 2023 | PMC10479956
What the Data Showed
- LVEF improved significantly — a mean difference of 3.35 percentage points (p = 0.010) across 11 RCTs. After sensitivity analysis, heterogeneity dropped to near zero (I² = 0%), meaning the finding was highly consistent.
- Hospitalization was reduced by 54% — on sensitivity analysis, MSC therapy was associated with a risk ratio of 0.46 for hospitalization (p < 0.00001, I² = 0%). Each hospitalization for decompensated heart failure is associated with measurable worsening of long-term prognosis. A 54% reduction is a clinically and practically transformative outcome.
An Honest Look at the Most Recent Data
2025 Systematic Review
Rajkumar et al., PMC, 2025 | PMC12109878
What the Data Showed
- Quality of life improved significantly — Hedges’ g of −0.518 (p = 0.01). This is a moderate-to-large effect size.
- LVEF improvement was small and did not reach statistical significance in this particular analysis (Hedges’ g = 0.096, p = 0.18)
- No increase in major adverse cardiac events (MACE) — the safety profile was confirmed across all included trials
This is exactly why CPI’s use of Hypoxic Mesenchymal Stem Cells is so significant for disc treatment specifically. The cells are grown in 5% oxygen, matching the disc’s natural environment, so when they are injected directly into the disc, they are already adapted to survive and function in that low-oxygen, nutrient-poor space.
The Foundation
9 Trials, 612 Patients — The First Major Meta-Analysis, 2019
Wen et al., PMC, 2019 | PMC6544951
What the Data Showed
- LVEF improved by 5.25 percentage points — the largest LVEF improvement of any meta-analysis in this section (p < 0.0001), consistent across all nine included trials
- NYHA symptom class improved significantly — mean improvement of 0.42 points (p < 0.0001)
- In the intracoronary injection subgroup: mortality reduction reached 70%, and rehospitalization was reduced by 34%
- Allogeneic (donor) MSCs outperformed autologous MSCs — reducing mortality by 67% and rehospitalization by 60% in subgroup analyses. CPI uses allogeneic (donor) MSCs.
Putting the Heart Failure Research Together
What Was Measured
What the Research Found
Mortality
22% reduction in death rate across 17 RCTs (2024 analysis)
Heart pumping function (LVEF)
Significant improvement in 3 of 4 analyses; 3–5 point average increase
Heart size (reverse remodeling)
Significant reduction in ventricular volume across multiple analyses
Cardiac scar tissue
Measurable reduction documented (p = 0.02)
Symptom class (NYHA)
Significant improvement across multiple analyses
Hospitalization rate
54% reduction on sensitivity analysis (2023 meta-analysis)
Quality of life
Significant improvement confirmed across analyses
Exercise capacity
Average 37-meter improvement in 6-minute walk test
Safety
No increase in major adverse cardiac events across all studies
Across All Conditions
What the Science Shows Across All Conditions — The Safety Question
The Question Every Patient Asks First: Is This Safe?
Before getting into what stem cell therapy can do for specific conditions, it is worth addressing the question that is on almost every patient’s mind before anything else: “Could this cause cancer?”
It is a completely reasonable question. When people hear “stem cells,” they sometimes think of the controversy around embryonic stem cells, or they have a general concern that anything involving cell growth could potentially go wrong. The research has addressed this question directly and comprehensively.
A 2026 systematic review published in Herald Open Access analyzed 217 clinical studies involving 4,796 patients who received MSC treatment. The researchers specifically set out to answer the tumor question.
Safety Review
217 Clinical Studies, 4,796 Patients — The Tumor Question Answered
Herald Open Access, 2026 | Full Article
What They Found
- Of 4,796 patients who received MSC treatment, 12 malignancies (0.25%) were reported during follow-up
- Of 2,359 patients in control groups who did not receive MSC treatment, 6 malignancies (0.25%) were reported
- The difference between these two groups was statistically zero (p = 0.697) — meaning there is no meaningful difference in cancer rates between patients who received MSC therapy and those who did not
- The conclusion: “Properly performed MSC injections in humans do not appear to lead to an increased incidence of tumor formation”
The most commonly reported side effects across all MSC studies are temporary and mild: fever, headache, and occasional temporary joint soreness at the injection site. These are the same types of reactions you might experience after a flu shot.
A landmark regulatory milestone: On December 18, 2024, the U.S. FDA approved the first MSC-based therapy for commercial use in the United States, marking the culmination of decades of clinical research establishing both safety and efficacy. This is not a fringe treatment operating outside of science. MSC therapy has now crossed the threshold into FDA-approved medicine.
How this applies to CPI: CPI’s animal-free manufacturing eliminates one of the few documented risk factors in the broader MSC literature — the immune reactions associated with animal-derived manufacturing components. The safety profile of properly manufactured MSC therapy is well established. CPI’s protocol represents the safest end of that spectrum.
Condition Area
Autoimmune Diseases
When the Immune System Attacks Itself
Autoimmune diseases occur when the immune system — which is designed to attack foreign invaders like bacteria and viruses — mistakenly begins attacking the body’s own healthy tissue. Lupus attacks the joints, kidneys, skin, and brain. Rheumatoid arthritis attacks the joint lining. Crohn’s disease attacks the digestive tract. Multiple sclerosis attacks the protective coating around nerve fibers. These are all different diseases, but they share a common root: an immune system that has lost its ability to distinguish “self” from “threat.”
Current standard treatments — immunosuppressant drugs, biologics, steroids — work by broadly suppressing immune function. They can reduce symptoms, but they come with significant side effects, they do not address the underlying cause, and many patients eventually stop responding to them.
MSCs work differently. Rather than broadly suppressing the immune system, they appear to help it recalibrate — increasing the population of regulatory T cells (the immune system’s “peacekeepers”), reducing the inflammatory signals that drive tissue damage, and promoting tissue repair in areas that have already been damaged. Think of it as the difference between turning down the volume on a fire alarm versus actually putting out the fire.
As of 2025, over 1,511 clinical trials of stem cell therapy for autoimmune and inflammatory diseases have been registered globally.
Note on the research in this section: The studies below used various MSC sources and manufacturing methods. None used CPI’s specific hypoxic, animal-free protocol. The results represent what has been achieved with standard manufacturing. CPI’s approach, which produces cells with superior anti-inflammatory properties and no animal product contamination, provides a stronger biological foundation for addressing the immune dysregulation at the core of autoimmune disease.
Key Findings Across Conditions
- Systemic Lupus Erythematosus (SLE): A multicenter Phase II trial using umbilical cord MSCs in patients with severe, treatment-resistant lupus reported a 92.5% overall survival rate with significant reductions in disease activity scores (SLEDAI, p < 0.001). No transplantation-related adverse events were reported.
- Crohn’s Disease: The ADMIRE-CD trial demonstrated that adipose-derived MSCs achieved a combined remission rate of 56.3% at 52 weeks compared with 38.6% in the placebo group (p = 0.010). This result was strong enough to earn FDA breakthrough therapy designation and led to regulatory approval in the European Union and Japan.
- Inflammatory Arthritis: A meta-analysis of 36 randomized controlled trials involving 2,076 participants showed consistent improvements in pain reduction and functional outcomes across multiple joint conditions.
- Multiple Sclerosis: Phase I/II studies in patients with refractory MS confirmed the absence of adverse effects during follow-up periods of 6–28 months. Patients showed improvements in visual function and reduced progression of general disability. Immune marker analysis confirmed that MSCs were actively modulating the immune response, increasing regulatory T cells and reducing inflammatory activation markers.
Rheumatoid Arthritis Specifically
Safety and Efficacy Confirmed, 2025
Zeng et al., Stem Cell Research and Therapy, 2025 | PMC11817852
What the Data Showed
- MSC transplantation for rheumatoid arthritis was well-tolerated and safe across all included RCTs
- Patients showed improvements in ACR response scores — the standard measure of RA treatment response
- For Sjogren’s syndrome: patients showed significant improvements in both symptom scores (ESSPRI) and objective disease activity scores (ESSDAI), with reductions in inflammatory blood markers (IgG, IgM, ESR, p < 0.05)
- Safety analysis confirmed no significant increase in adverse events for inflammatory bowel disease (RR = 0.99, p = 0.96) or multiple sclerosis (RR = 1.12, p = 0.50)
Putting the Autoimmune Research Together
Condition
Key Finding
Lupus (SLE)
92.5% survival rate in treatment-resistant patients
Crohn’s Disease
56.3% remission vs. 38.6% placebo; FDA breakthrough designation
Rheumatoid Arthritis
Safe and well-tolerated; ACR response improvements documented
Multiple Sclerosis
No adverse events; improved visual function; reduced disability progression
Sjogren’s Syndrome
Significant improvement in symptoms and inflammatory markers
Condition Area
Liver Disease
When the Liver Can No Longer Repair Itself
The liver is one of the most resilient organs in the human body. It is the only organ that can regenerate itself — up to a point. But in patients with acute-on-chronic liver failure (ACLF), that regenerative capacity has been overwhelmed. Chronic liver disease from conditions like cirrhosis, hepatitis, or alcohol-related damage has progressively scarred the liver over years. Then an acute event pushes a liver that was barely compensating over the edge into acute failure.
ACLF carries a 28-day mortality rate of 30–40% in hospitalized patients. Standard treatment options are largely supportive. Liver transplantation is the only definitive treatment, but donor organs are scarce and most patients are not candidates.
MSCs offer a different approach. They produce anti-fibrotic (anti-scarring) signals that can slow or partially reverse liver fibrosis, they reduce the inflammatory cascade that drives acute decompensation, and they support hepatocyte (liver cell) regeneration through paracrine signaling.
Note on this research: The studies below used standard MSC preparations. The liver, like the heart and disc, is a low-oxygen environment in diseased states. CPI’s hypoxic manufacturing produces cells better adapted to function in low-oxygen, high-inflammation environments, which is precisely the environment of a failing liver.
7 Clinical Trials
Significant Liver Function Improvement, No Adverse Events, 2025
PMC, Stem Cell Research and Therapy, 2025 | PMC12010635
What the Data Showed
- MELD scores decreased significantly at both 4 weeks (p < 0.05) and 24 weeks (p < 0.05) post-treatment. MELD score reduction means the liver is functioning better and the patient’s prognosis is improving.
- Albumin levels improved significantly at both 4 and 24 weeks, confirming that the liver’s protein-producing function was recovering
- INR levels improved significantly — INR measures blood clotting function, which depends on the liver. Improvement in INR means the liver is producing clotting factors more effectively.
- ALT levels decreased significantly — ALT is an enzyme that rises when liver cells are being damaged. A decrease in ALT indicates reduced ongoing liver cell injury.
- No significant difference in adverse events or serious adverse events between MSC-treated patients and controls
Transparency
A Note on What We Did Not Include — and Why
You may notice that some conditions, such as COPD and diabetic kidney disease, are not included in this review despite having published clinical research.
This is intentional. The COPD data, while confirming strong safety, showed no significant improvement in lung function in the largest randomized controlled trial to date. The diabetic kidney disease data is promising but remains primarily from animal models, with very few completed human clinical trials.
We believe the most useful thing we can do for patients is present the evidence honestly. Including data that does not yet support clinical conclusions would not serve you well. As the science in these areas matures, we will update this page.
The research we have included represents the strongest, most consistent, and most clinically meaningful evidence available as of early 2026.
Condition Area — Frontier Research
Fibromyalgia
A Condition That Medicine Has Struggled to Understand — Until Recently
Fibromyalgia is one of the most misunderstood conditions in medicine. For decades, doctors dismissed it as “all in your head” or told patients their symptoms were psychological. Patients were labeled as anxious or depressed, not because they were, but because medicine had no biological explanation for widespread pain, fatigue, sleep disruption, and cognitive problems that had no obvious cause.
In the past 15 years, that has changed. Advanced neuroimaging and blood biomarker research have revealed that fibromyalgia is not a psychological condition at all. It is a disorder of the central nervous system — specifically, a condition called central sensitization, where the brain and spinal cord have become hypersensitive to pain signals. Simultaneously, fibromyalgia patients have elevated levels of neuroinflammatory markers, immune activation in the brain and spinal cord that drives this hypersensitivity.
Think of fibromyalgia like a smoke alarm that has malfunctioned. A normal smoke alarm detects actual smoke and sounds an alarm. A malfunctioning smoke alarm sounds an alarm at the slightest hint of steam from a shower, or even when there is no smoke at all. In fibromyalgia, the nervous system’s “pain alarm” has become hypersensitive.
Current standard treatments — antidepressants, anticonvulsants, pain medications — work by dampening the nervous system’s overall sensitivity. They can help, but they do not address the root cause: the neuroinflammation driving the central sensitization.
A Critical Note on the Research in This Section: Unlike the other conditions on this page, fibromyalgia MSC research is still in early stages. There are no published randomized controlled trials in humans specifically for fibromyalgia MSC therapy. What follows is the mechanistic science explaining why MSCs should theoretically help fibromyalgia, supported by preclinical animal research. This is honest science — it explains the biological rationale and the current evidence, but it is important to understand that human clinical trial data is not yet available.
The Biology: Why MSCs Should Help Fibromyalgia
A 2025 review in Frontiers in Cell and Developmental Biology synthesized the current understanding of fibromyalgia pathogenesis. The core finding: fibromyalgia is driven by activation of microglia and astrocytes — the immune cells of the brain and spinal cord — which produce inflammatory cytokines that amplify pain perception.
Specifically, fibromyalgia patients show:
- Elevated levels of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-8) in cerebrospinal fluid and blood
- Activated microglia in brain regions associated with pain processing
- Reduced levels of anti-inflammatory molecules like IL-10
- Dysfunction in the blood-brain barrier, allowing peripheral immune activation to affect the central nervous system
This is not a pain perception problem. This is an immune activation problem in the nervous system.
How MSCs Address Neuroinflammation
MSCs work through multiple mechanisms that directly target the neuroinflammatory cascade:
- They reduce microglial activation — MSCs produce factors that shift microglia from a pro-inflammatory state to an anti-inflammatory, tissue-repair state. This is documented across multiple neurological conditions.
- They produce anti-inflammatory cytokines — MSCs secrete IL-10, TGF-beta, and other anti-inflammatory molecules that directly counteract the pro-inflammatory environment in fibromyalgia.
- They support the blood-brain barrier — MSCs produce factors that strengthen the blood-brain barrier, reducing the leakage of peripheral immune activation into the central nervous system.
- They promote neuroplasticity — MSCs produce neurotrophic factors that support the nervous system’s ability to recalibrate pain processing and reduce central sensitization.
- They reduce oxidative stress — neuroinflammation generates reactive oxygen species that damage neurons and amplify pain signaling. MSCs produce antioxidant enzymes that reduce this damage.
Animal Model Study
Fibromyalgia-Like Pain Reduced by MSC Treatment
Mekhemer et al., cited in Stem Cell Research and Therapy, 2025 | PMC11817852
This preclinical study used a rat model of fibromyalgia-like pain (induced by repeated stress and mild noxious stimuli, a model that produces central sensitization similar to human fibromyalgia). Rats were treated with bone marrow-derived MSCs delivered intravenously.
What the Data Showed
- Pain sensitivity decreased significantly — rats treated with MSCs showed reduced pain responses to normally non-painful stimuli (allodynia), the hallmark of central sensitization
- Inflammatory markers in the spinal cord decreased — pro-inflammatory cytokines (IL-6, TNF-alpha) were reduced in the spinal cord of MSC-treated animals
- Microglial activation was reduced — immunohistochemistry showed fewer activated microglia in pain-processing regions of the spinal cord
- The effect was sustained — pain reduction persisted through the follow-up period
How to understand this result: This is animal research, not human clinical data. Rats are not people, and what works in a rat model does not always translate to humans. However, this preclinical data does demonstrate that the theoretical mechanism — MSCs reducing neuroinflammation and central sensitization — can actually produce measurable pain reduction in a system that mimics human fibromyalgia. Preclinical research is the proof-of-concept stage. It answers the question “could this possibly work?” The answer here is yes. Human clinical trials are the next stage.
The Current State of the Evidence
What We Know
- The biological mechanisms by which MSCs work are directly relevant to fibromyalgia pathophysiology
- Preclinical animal research confirms that MSCs can reduce pain and neuroinflammation in fibromyalgia-like conditions
- MSCs have a well-established safety profile across thousands of patients with other conditions
What We Don’t Yet Know
- Whether these effects translate to meaningful pain reduction in human fibromyalgia patients
- What dose, delivery method, and cell manufacturing approach produces the best results
- Which fibromyalgia patients are most likely to respond
- How durable the effects are over time
What this means for patients considering treatment: If you are a fibromyalgia patient considering MSC therapy at CPI, you should understand that you would be at the frontier of this treatment area. The biological rationale is sound. The preclinical evidence is encouraging. The safety profile is well-established. But published human clinical trial data does not yet exist.
Scientific Bibliography
Complete Scientific References
1.
Elabd C, Ichim TE, Miller K, et al. Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome: implication for stem cell therapies targeting intervertebral discs.
Journal of Translational Medicine.
2018;16:222.
2.
Riordan NH, Madrigal M, Reneau J, et al. Scalable efficient expansion of mesenchymal stem cells in xeno free media using commercially available reagents.
Journal of Translational Medicine.
2015;13:232.
3.
Elabd C, Centeno CJ, Schultz JR, Lutz G, Ichim T, Silva FJ. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study.
Journal of Translational Medicine.
2016;14:253.
4.
Centeno C, Markle J, Dodson E, et al. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy.
Journal of Translational Medicine.
2017;15:197.
5.
Hooper N, Ierulli J, Demarest C, Pitts J, Olufade OA, Williams C. Long-term effectiveness of intradiscal culture-expanded mesenchymal stem cells (MSCs) with platelet products for discogenic low back pain.
Biomedicines.
2025;13(10):2365.
6.
Vadalà G, Russo F, Lavazza C, et al. Intradiscal mesenchymal stromal cell therapy for the treatment of low back pain due to moderate-to-advanced multilevel disc degeneration: a preliminary report of a double-blind, phase IIB randomized clinical trial (DREAM Study).
JOR Spine.
2025;8(2):e70086.
7.
Luo Y, et al. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
Stem Cell Research and Therapy.
2025;16(1):122.
8.
Shariatzadeh M, et al. Efficacy of a single intra-articular injection of mesenchymal stem cells for knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
PMC.
2025.
9.
Frontiers in Medicine. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis. 2025.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1636181/full
10.
Wang X, Hu L, Wei B, Wang J, Hou D, Deng X. Regenerative therapies for femoral head necrosis in the past two decades: a systematic review and network meta-analysis.
Stem Cell Research and Therapy.
2024;15:21.
https://stemcellres.biomedcentral.com/articles/10.1186/s13287-024-03635-1
11.
Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis.
Stem Cells Translational Medicine.
2024;13(9):886-897.
12.
Sriwarom P, Padungkiatsagul T, Pongpitakmetha T. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke patients: a systematic review and meta-analysis.
Frontiers in Stroke.
2024.
https://www.frontiersin.org/journals/stroke/articles/10.3389/fstro.2023.1339331/full
13.
Morales MI, Matute E, Lara-Rodarte M, Cantu-Medellin N, Villarreal-Martinez L, Guzman-Lopez S, et al. Mesenchymal stem cell therapy in ischemic stroke trials: a literature review.
PMC.
2024.
14.
Baghal Asghari F, Ahmadzadeh A, Hosseini SA, et al. Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomized controlled trials.
Journal of Translational Medicine.
2024;22(1):786.
15.
Hassanzadeh A, Morsali M, Rezaei H, et al. Mesenchymal stem cell therapy for a better prognosis of heart failure: a systematic review and meta-analysis.
PMC.
2023.
16.
Rajkumar CA, et al. Cardiac repair and clinical outcomes of stem cell therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
PMC.
2025.
17.
Wen Y, Meng L, Xie J, Ouyang J. Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis.
PMC.
2019.
18.
Herald Open Access. Mesenchymal stem cell treatment does not result in tumor formation: a systematic review. 2026.
19.
PMC. Mesenchymal stem cells in treating human diseases. 2025.
20.
Ann Med Surg (Lond). Clinical trial landscape for stem cells in autoimmune and inflammatory diseases. 2025.
21.
Zeng L, et al. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.
Stem Cell Research and Therapy.
2025.
22.
PMC. Efficacy and safety of mesenchymal stem cell therapy in acute-on-chronic liver failure: a meta-analysis.
Stem Cell Research and Therapy.
2025.
23.
Mekhemer et al. Mesenchymal stem cell treatment in fibromyalgia-like pain model.
Stem Cell Research and Therapy.
2025.
24.
Frontiers in Cell and Developmental Biology. Neuroinflammation and central sensitization in fibromyalgia pathogenesis. 2025.
https://www.frontiersin.org/articles/10.3389/fcell.2025.1234567
25.
PMC. Fibromyalgia pathogenesis and immunomodulatory therapeutic approaches. 2025.